Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Given the findings of SUNSET, demonstrating 60 Gy in 8 fractions to be a safe and effective regimen for ultracentral lesions, in what situations would you elect to use a 10 fraction hypofractionated regimen?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?
